Methods of mediating macrophage phenotypes
View Patent ↗Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages. A blood fraction including platelet-poor plasma polarizes the source of macrophages into M1 macrophages. A blood faction including a protein solution polarizes the source of macrophages into M2 macrophages.
1. A method for mediating the phenotype of macrophages, consisting of:
(a) obtaining a blood-derived composition; and
(b) contacting an isolated source of macrophages with the blood-derived composition and optionally a non-differentiating growth media, wherein contacting the macrophages with the blood-derived composition induces the macrophages to a polarized phenotype.
2. The method according to claim 1 , wherein the source of macrophages is a composition comprising monocytes.
3. The method according to claim 1 , wherein the blood-derived composition is platelet-poor plasma, and wherein the source of macrophages is polarized to M1 macrophages.
4. The method according to claim 1 , wherein the blood-derived composition is a protein solution comprising interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-1 receptor antagonist (IL-1ra), and transforming growth factor-β (TGF-β), and wherein the source of macrophages are polarized to M2 macrophages.
5. The method according to claim 1 , wherein step (a) consists of contacting whole blood, bone marrow aspirate, a fraction thereof, a concentrate thereof, or a combination thereof, with polyacrylamide beads to form an activating composition, and separating the activating composition from the polyacrylamide beads to produce the blood-derived composition.
6. The method according to claim 1 , wherein the blood-derived composition comprises whole blood, platelet rich plasma, bone marrow aspirate, a bone marrow concentrate, a protein solution, or platelet poor plasma, a fraction thereof, a concentrate thereof, or a combination thereof.
7. The method according to claim 1 , wherein the source of macrophages is peripheral blood, tissue at or near a site of inflammation in a donor, or a culture medium comprising monocytes.
8. The method according to claim 1 , wherein the source of macrophages is a concentrated macrophage solution generated by fractionating peripheral blood or bone marrow aspirate obtained from a donor.
9. A method for inducing M2 polarization of macrophages, consisting of:
(a) obtaining a blood-derived composition comprising interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-1 receptor antagonist (IL-1ra), transforming growth factor β-1 (TGFβ-1), or a combination thereof; and
(b) contacting an isolated source of macrophages with the blood-derived composition, wherein contacting the macrophages with the blood-derived composition induces the macrophages to polarize to an M2 phenotype.
10. The method according to claim 9 , wherein the blood-derived composition consists of whole blood, platelet rich plasma, a protein solution, lipoaspirate, bone marrow aspirate, a fraction thereof, a concentrate thereof, or a combination thereof.
11. The method according to claim 9 , wherein the blood-derived composition is platelet-rich plasma.
12. The method according to claim 9 , wherein step (a) consists of contacting whole blood, bone marrow aspirate, lipoaspirate, a fraction thereof, a concentrate thereof, or a combination thereof, with polyacrylamide beads to form a concentrated composition, and separating the concentrated composition from the polyacrylamide beads to produce the blood-derived composition.
13. The method according to claim 9 , wherein the concentration of IL-4, IL-10, IL-1ra, or TGFβ-1 in the blood-derived composition is greater than the respective concentration of IL-4, IL-10, IL-1ra, or TFBβ-1 in whole blood.
14. A method for mediating the phenotype of macrophages, consisting of:
(a) obtaining a composition comprising interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-1 receptor antagonist (IL-1ra), transforming growth factor β-1 (TGF-β-1), or a combination thereof, wherein the IL-4, IL-10, IL-1ra, TGF-β-1 is derived from blood, bone marrow aspirate, lipoaspirate, a fraction thereof, a concentrate thereof, or a combination thereof; and
(b) culturing an isolated source of macrophages in a activating composition consisting of the composition and optionally a non-differentiating growth media for a period of time, wherein the macrophages display a polarized phenotype after the period of time.
15. The method according to claim 14 , wherein the period of time is at least twelve hours.
16. The method according to claim 14 , wherein the period of time is about ten days.
17. The method according to claim 14 , wherein the composition comprises about 25% by volume of the culture medium.
18. The method according to claim 14 , wherein at least about 50% of the macrophages display an M2 phenotype after the period of time.
19. The method according to claim 14 , wherein step (a) includes contacting blood, bone marrow aspirate, lipoaspirate, a fraction thereof, a concentrate thereof, or a combination thereof, with a concentrating material to form an activating composition, and separating the activating composition from the concentrating material to form the blood-derived composition.
20. The method according to claim 14 , wherein the concentration of at least one of IL-4, IL-10, IL-1ra, or TGFβ-1 in the composition is greater than the respective concentration of IL-4, IL-10, IL-1ra, or TFBβ-1 in whole blood.